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Here we report the draft genome sequence of Streptomyces toyocaensis strain NRRL 15009 which is the producer of the glycopep-
tide antibiotic A47934. The genome sequence is predicted to harbor a total of 26 secondary metabolite biosynthetic gene clusters
including the A47934 cluster.
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Streptomyces toyocaensis strain NRRL 15009 was isolated from asandy soil sample in the state of Washington, USA and de-
scribed as the producer of A47934 (1). A47934 belongs to the
glycopeptide family of antibiotics, an important class of antibiot-
ics which also includes vancomycin and teicoplanin which are
currently reserved in the clinic as the last-resort treatment of in-
fectious disease caused by Gram-positive pathogens that are resis-
tant to the antibiotics in mainstream use. A47934 is a sugarless
glycopeptide antibiotic with a heptapeptide backbone structure
closely related to that of teicoplanin, but is unique among re-
ported glycopeptides as it contains a sulfate ester group. The com-
plete sequence of the A47934 synthetic gene cluster in S. toyocaen-
sis NRRL 15009 has previously been determined, and consists of
34 contiguous open reading frames (ORFs) encompassing 69 kb
of chromosomal DNA (GenBank accession no. STU82965) (2).
Here we present the first draft of the entire genome sequence of
S. toyocaensis NRRL 15009.
The genome was sequenced to a coverage depth of 53-fold
using a 454 GS-FLX instrument (Roche) with 454 titanium chem-
istry, and assembled using Newbler v2.5.3. This produced 87 con-
tigs from 1,110,442 reads, and a total estimated genomic size of
7,341,583 bp. The genome has a GC content of 72.04%. The
average contig size is 97,848 bp and the largest contig size is
891,334 bp. Genome annotation was performed by the Prokary-
otic Genome Annotation Pipeline (PGAP) with GeneMarkS (3,
4), and identified 6,315 coding sequence (CDS) regions, 82 pseu-
dogenes, and 65 tRNAs. A single copy of each 5S rRNA, 16S rRNA,
and 23S rRNA were also predicted in the draft genome sequence.
The biosynthetic cluster of A47934 is located at 254,157 bp to
323,457 bp in the draft genome (on contig 1). This region also
includes genes (vanRst, vanSst, vanHst, vanAst, vanXst, murX,
staO, and staP) required for conferring self-resistance to the
A47934 antibiotic. Using antiSMASH (5), a further 25 biosyn-
thetic clusters potentially capable of producing secondary metab-
olites were also identified. These include three predicted to encode
production of lantipeptides, two bacteriocin clusters, two sidero-
phore clusters, three butyrolactone clusters, four nonribosomal
peptide synthease (NRPS) clusters, four clusters encoding ter-
penes, a phenazine cluster, the ectoine biosynthesis cluster, and
one type II-polyketide synthease (PKS) cluster.
The availability of the S. toyocaensis NRRL 15009 genome se-
quence will consequently assist with the search for new bioactive
compounds of microbial origin, and will facilitate studies into
resistance mechanisms and the regulation of secondary metabo-
lite production.
Nucleotide sequence accession numbers. The draft genome
sequence of S. toyocaensis NRRL 15009 has been deposited in the
DDBJ/EMBL/GeneBank database under the accession no.
JFCB00000000. The version described in this paper is version
JFCB01000000.
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